Dashboard
Manage Tickers

RGNXREGENXBIO Inc.

Nasdaq regenxbio.com


$ 11.63 $ 0.12 (1.04 %)    

Thursday, 27-Jun-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 11.63
$ 11.33
$ 0.00 x 0
$ 11.63 x 148
$ 11.33 - $ 11.89
$ 11.33 - $ 28.80
482,674
na
531.87M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-06-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-07-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 03-03-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-is-clearside-biomedical-stock-gaining-today
Why Is Clearside Biomedical Stock Gaining ...
06/25/2024 16:54:36

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer ra...

regenxbio-expands-its-affinity-duchenne-trial-to-include-a-new-cohort-of-younger-patients
REGENXBIO Expands Its AFFINITY DUCHENNE Tr...
06/24/2024 11:06:35

fda-approves-expanded-use-for-sareptas-rare-muscular-dystrophy-gene-therapy
FDA Approves Expanded Use For Sarepta's Ra...
06/21/2024 11:39:52

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older w...

hc-wainwright--co-reiterates-buy-on-regenxbio-maintains-38-price-target
HC Wainwright & Co. Reiterates Buy on Rege...
06/20/2024 15:25:46

HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $38 price target.

regenxbio-concludes-pre-biologics-license-application-meeting-for-rgx-121-for-mucopolysaccharidosis-type-ii-where-it-finalized-details-of-its-application-with-the-fda-expects-to-initiate-submission-of-a-rolling-bla-in-q3-of-2024
Regenxbio Concludes Pre-biologics License ...
06/18/2024 11:11:31

Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval p...

regenxbio-reiterated-its-financial-guidance-previously-provided-on-may-8-2024
Regenxbio Reiterated Its Financial Guidanc...
06/12/2024 11:11:00

regenxbio-announced-that-curran-simpson-chief-operating-officer-has-been-appointed-as-president-chief-executive-officer-and-a-member-of-the-board-of-directors-effective-july-1-2024
REGENXBIO Announced That Curran Simpson, C...
06/12/2024 11:08:17

goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside
Goldman Sachs Optimistic About Regenxbio's...
06/07/2024 18:30:54

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

assessing-regenxbio-insights-from-4-financial-analysts
Assessing Regenxbio: Insights From 4 Finan...
06/07/2024 14:00:25

goldman-sachs-initiates-coverage-on-regenxbio-with-buy-rating-announces-price-target-of-38
Goldman Sachs Initiates Coverage On Regenx...
06/07/2024 11:28:34

Goldman Sachs analyst Paul Choi initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price Target o...

evaluating-regenxbio-insights-from-9-financial-analysts
Evaluating Regenxbio: Insights From 9 Fina...
05/15/2024 19:02:40

hc-wainwright--co-maintains-buy-on-regenxbio-raises-price-target-to-38
HC Wainwright & Co. Maintains Buy on Regen...
05/15/2024 15:31:02

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and raises the price target from $36 to...

regenxbio-q1-2024-gaap-eps-138-misses-123-estimate-sales-15622m-miss-23525m-estimate
Regenxbio Q1 2024 GAAP EPS $(1.38) Misses ...
05/08/2024 21:37:56

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.23) b...

where-regenxbio-stands-with-analysts
Where Regenxbio Stands With Analysts
04/12/2024 16:01:22

stifel-maintains-buy-on-regenxbio-maintains-40-price-target
Stifel Maintains Buy on Regenxbio, Maintai...
04/12/2024 15:53:51

Stifel analyst Annabel Samimy maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $40 price target.

Core News & Articles
REGENXBIO Announces Lancet Publication of ...
03/28/2024 11:09:41

REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and to...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
03/25/2024 21:32:19

hc-wainwright--co-initiates-coverage-on-regenxbio-with-buy-rating-announces-price-target-of-36
HC Wainwright & Co. Initiates Coverage On ...
03/11/2024 13:39:24

HC Wainwright & Co. analyst Yi Chen initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price ...

this-gene-therapy-player-duchenne-data-is-impressive-analyst-upgrades-regenxbio
This Gene Therapy Player Duchenne Data Is ...
03/08/2024 18:43:05

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 t...

regenxbio-shares-are-trading-higher-after-rbc-capital-upgraded-the-stock-from-sector-perform-to-outperform-and-raised-its-price-target-from-20-to-35
Regenxbio shares are trading higher after ...
03/08/2024 13:48:00

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)